Skip to main content

triptorelin

Generic: TRIPTORELIN PAMOATE·Brand: TRELSTAR, TRIPTODUR KIT, Trelstar

triptorelin: 11 clinical trials tracked.

triptorelin evidence translation

What we can confirm

11 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about triptorelin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 5 study sponsors
Clinical Trials (11)showing 10 most recent

Copenhagen Menopause Study (COMPASS): A Randomized Clinical Trial

NCT07254429·Phase 2·CDTX
Recruiting

Primary endpoint: Change in bone remodeling from baseline to week 8.

InterventionalRandomizedsingle192 targetStarted 2025-10Completion 2028-051 site · DenmarkMartin Blomberg Jensen

Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer

NCT06513962·Phase 3
Recruiting

Primary endpoint: Number of enrollments of newly diagnosed AYA female cancer patients age < 40 years

InterventionalRandomizedopen60 targetStarted 2025-02Completion 2029-1050 sites · United StatesChildren's Oncology Group

MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer

NCT06378866·Phase 2·KYNB
Recruiting

Primary endpoint: Modified radiographic progression-free survival (mrPFS) (Groups A & B)

InterventionalRandomizedopen532 targetStarted 2024-06Completion 2029-053 sites · United StatesMayo Clinic

Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland

Completed

Primary endpoint: Body Mass Index (BMI)

Observational1,083 enrolledStarted 2023-02Completion 2024-041 site · FinlandPfizer

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

NCT05050084·Phase 3·CGON
Active, not recruiting

Primary endpoint: Distant metastasis (DM) (De-intensification study)

InterventionalRandomizedopen2,050 targetStarted 2021-12Completion 2026-1150 sites · United StatesNRG Oncology

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

NCT04484818·Phase 3
Active, not recruiting

Primary endpoint: Metastasis-free survival (MFS)

InterventionalRandomizeddouble27 enrolledStarted 2021-03Completion 2028-0550 sites · United StatesECOG-ACRIN Cancer Research Group

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

NCT04513717·Phase 3·CGON
Active, not recruiting

Primary endpoint: Metastasis-free survival (MFS)

InterventionalRandomizedopen2,753 enrolledStarted 2021-01Completion 2038-1250 sites · United StatesNRG Oncology

Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

NCT04423211·Phase 3
Recruiting

Primary endpoint: Progression-free survival (PFS)

InterventionalRandomizedopen804 targetStarted 2020-10Completion 2032-1250 sites · United StatesECOG-ACRIN Cancer Research Group

An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer

NCT02278185·Phase 2·KYNB
Completed

Primary endpoint: Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria

InterventionalRandomizedopen19 enrolledStarted 2015-11Completion 2024-072 sites · United StatesUniversity of Colorado, Denver

A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer

NCT00066690·Phase 3
Completed

Primary endpoint: Disease-free Survival

InterventionalRandomizedopen3,066 enrolledStarted 2003-12Completion 2024-1150 sites · United StatesETOP IBCSG Partners Foundation